Akero Therapeutics is a leading cardio-metabolic biotechnology company that is revolutionizing the treatment of non-alcoholic steatohepatitis (NASH), a serious metabolic disease. With a focus on restoring balance and renewing life, Akero is dedicated to transforming the lives of people living with this condition. At the forefront of their innovative product line is Efruxifermin (EFX), an investigational drug that shows great promise as a potentially best-in-class treatment for NASH.

Akero Therapeutics has ongoing clinical trials to evaluate the safety and efficacy of EFX, aiming to provide a much-needed solution for patients. With a commitment to patient health, Akero Therapeutics is actively seeking talented individuals who are passionate about making a difference in the lives of patients. They offer exciting job opportunities in a culture that fosters innovation and growth.

Stay up-to-date with the latest advancements and press releases from Akero Therapeutics as they continue to advance in their mission to transform the field of metabolic disease treatment